Probabilistic drug connectivity mapping

BMC Bioinformatics

Juuso A Parkkinen²  Samuel Kaski¹ 

[1] Helsinki Institute for Information Technology HIIT, Department of Computer Science, University of Helsinki, Helsinki, Finland

[2] Helsinki Institute for Information Technology HIIT, Department of Information and Computer Science, Aalto University, Espoo, Finland

关键词: Probabilistic modeling;    Latent variable models;    Gene expression;    Data integration;    Connectivity mapping;   

Others  :  818658
DOI  :  10.1186/1471-2105-15-113

 received in 2013-12-18, accepted in 2014-04-14,  发布年份 2014

【 摘 要 】

Background

The aim of connectivity mapping is to match drugs using drug-treatment gene expression profiles from multiple cell lines. This can be viewed as an information retrieval task, with the goal of finding the most relevant profiles for a given query drug. We infer the relevance for retrieval by data-driven probabilistic modeling of the drug responses, resulting in probabilistic connectivity mapping, and further consider the available cell lines as different data sources. We use a special type of probabilistic model to separate what is shared and specific between the sources, in contrast to earlier connectivity mapping methods that have intentionally aggregated all available data, neglecting information about the differences between the cell lines.

Results

We show that the probabilistic multi-source connectivity mapping method is superior to alternatives in finding functionally and chemically similar drugs from the Connectivity Map data set. We also demonstrate that an extension of the method is capable of retrieving combinations of drugs that match different relevant parts of the query drug response profile.

Conclusions

The probabilistic modeling-based connectivity mapping method provides a promising alternative to earlier methods. Principled integration of data from different cell lines helps to identify relevant responses for specific drug repositioning applications.

【 授权许可】

   
2014 Parkkinen and Kaski; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR: The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313(5795):1929-1935.
• [2]Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, di Bernardo D: Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Nat Acad Sci 2010, 107(33):14621-14626.
• [3]Qu XA, Rajpal DK: Applications of connectivity map in drug discovery and development. Drug Discov Today 2012, 17(23-24):1289-1298.
• [4]Iorio F, Rittman T, Ge H, Menden M, Saez-Rodriguez J: Transcriptional data: a new gateway to drug repositioning? Drug Discov Today 2013, 18(7-8):350-357.
• [5]Iskar M, Zeller G, Blattmann P, Campillos M, Kuhn M, Kaminska K. H, Runz H, Gavin A-C, Pepperkok R, van Noort V, Bork P: Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding. Mol Syst Biol 2013., 9(1) [http://msb.embopress.org/content/9/1/662.long webcite]
• [6]Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Nat Acad Sci USA 2005, 102(43):15545-15550.
• [7]Hotelling H: Relations between two sets of variates. Biometrika 1936, 28(3/4):321-377.
• [8]Khan S, Faisal A, Mpindi J, Parkkinen J, Kalliokoski T, Poso A, Kallioniemi O, Wennerberg K, Kaski S: Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs. BMC Bioinformatics 2012, 13(1):112. BioMed Central Full Text
• [9]Lin D, Zhang J, Li J, Calhoun V, Deng HW, Wang YP: Group sparse canonical correlation analysis for genomic data integration. BMC Bioinformatics 2013, 14(1):245. BioMed Central Full Text
• [10]Huopaniemi I, Suvitaival T, Kaski S, Nikkilä J: Multivariate multi-way analysis of multi-source data. Bioinformatics 2010, 26(12):391-398.
• [11]Virtanen S, Klami A, Khan SA, Kaski S: Bayesian Group Factor Analysis. In Proceedings of the Fifteenth International Conference on Artificial Intelligence and Statistics. Volume 22.. JMLR W&CP; 2012:1269-1277. Implementation in R available at [http://research.ics.aalto.fi/mi/software/CCAGFA/ webcite]
• [12]Hopkins A, Mason J, Overington J: Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006, 16(1):127-136.
• [13]Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL: Predicting new molecular targets for known drugs. Nature 2009, 462(7270):175-181.
• [14]Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, Bork P: Drug-induced regulation of target expression. PLoS Comput Biol 2010, 6(9):1000925.
• [15]Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT: Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 2010, 116(26):5983-5990.
• [16]Jia J, Zhu F, Ma X, Cao Z, Cao ZW, Li Y, Li YX, Chen YZZ: Mechanisms of drug combinations: interaction and network perspectives. Nat Reviews Drug Discov 2009, 8(2):111-128.
• [17]Al-Lazikani B, Banerji U, Workman P: Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotech 2012, 30(7):679-692.
• [18]Caldas J, Kaski S: Hierarchical generative biclustering for microRNA expression analysis. J Comput Biol: J Comput Mol Cell Biol 2011, 18(3):251-261.
• [19]Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31(4):e15.
• [20]Thurstone L: Multiple factor analysis. Psychol Rev 1931, 38(5):406-427.
• [21]Bishop CM: Variational principal components. In Artificial Neural Networks, 1999. ICANN 99. Ninth International Conference on (Conf. Publ. No. 470), Volume 1.. IEE; 1999. [http://research.microsoft.com/apps/pubs/default.aspx?id=67241 webcite]
• [22]Archambeau C, Bach F: Sparse probabilistic projections. In Advances in Neural Information Processing Systems, Volume 21. Cambridge, MA: MIT Press; 2009:73-80. [http://dblp.uni-trier.de/rec/bibtex/conf/nips/ArchambeauB08 webcite]
• [23]WHO Collaborating Centre for Drug Statistics Methodology: ATC classification index with DDDs, 2013 (Oslo 2012). [http://www.whocc.no/atc_ddd_index/ webcite]
• [24]Guha R: Chemical informatics functionality in R. J Stat Softw 2007, 18(5):1-16.